HRP20120682T1 - Protutumorski farmaceutski sastav koji sadr“i polipeptidne fragmente od seralizina - Google Patents
Protutumorski farmaceutski sastav koji sadr“i polipeptidne fragmente od seralizina Download PDFInfo
- Publication number
- HRP20120682T1 HRP20120682T1 HRP20120682TT HRP20120682T HRP20120682T1 HR P20120682 T1 HRP20120682 T1 HR P20120682T1 HR P20120682T T HRP20120682T T HR P20120682TT HR P20120682 T HRP20120682 T HR P20120682T HR P20120682 T1 HRP20120682 T1 HR P20120682T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- fragments
- composition
- use according
- alone
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title claims abstract 13
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 4
- 108090000899 Serralysin Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 230000000259 anti-tumor effect Effects 0.000 claims abstract 5
- 230000001939 inductive effect Effects 0.000 claims abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 230000003449 preventive effect Effects 0.000 claims abstract 2
- 230000001225 therapeutic effect Effects 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims 9
- 230000001575 pathological effect Effects 0.000 claims 4
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 2
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 238000010353 genetic engineering Methods 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 230000001640 apoptogenic effect Effects 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000037983 regulatory factors Human genes 0.000 claims 1
- 108091008025 regulatory factors Proteins 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/265—Enterobacter (G)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Farmaceutski sastav, naznačen time, da sadr·i jedan ili vi®e fragmenata seralizina koji imaju aminokiselinsku sekvencu odabranu iz skupine koju čine: SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID No 10, SEQ ID No 11, SEQ ID No 12, SEQ ID No 13, SEQ ID No 14, SEQ ID No 15 i SEQ ID No 16, za uporabu u induciranju protutumorskih djelovanja u receptivnom organizmu, pri čemu su spomenuta protutumorska djelovanja terapeutska ili preventivna. Patent sadr·i jo® 11 patentnih zahtjeva.
Claims (12)
1. Farmaceutski sastav, naznačen time, da sadrži jedan ili više fragmenata seralizina koji imaju aminokiselinsku sekvencu odabranu iz skupine koju čine:
SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID No 10,
SEQ ID No 11, SEQ ID No 12, SEQ ID No 13, SEQ ID No 14, SEQ ID No 15 i
SEQ ID No 16, za uporabu u induciranju protutumorskih djelovanja u receptivnom organizmu, pri čemu su spomenuta protutumorska djelovanja terapeutska ili preventivna.
2. Farmaceutski sastav za uporabu prema zahtjevu 1, naznačen time, da se spomenuti fragmenti seralizina dobivaju iz ustajale stanične kulture, pomoću genetske manipulacije ili pomoću kemijske sinteze.
3. Sastav za uporabu prema zahtjevima 1 i 2, naznačen time, da se spomenuti fragmenti pojavljuju u sastavu sami, konjugirani ili izmiješani.
4. Sastav za uporabu prema bilo kojem od zahtjeva 1 do 3, naznačen time, da su spomenuti fragmenti seralizina dio himernnih ili hibridnih molekula dobivenih pomoću genetske manipulacije ili kemijskom sintezom.
5. Fragmenti seralizina, naznačeni time, da su odabrani iz skupine koju čine SEQ ID NO 1 – 4 i SEQ ID NO 10 – 16 za uporabu u liječenju proliferativnih bolesti.
6. Fragmenti seralizina za uporabu prema zahtjevu 5, naznačeni time, da su spomenuti fragmenti dio sastava koji sadrži protutijela, fragmente protutijela, strukturna vlakna nukleinske kiseline, ili molekule ugljikohidrata ili molekule proteina, i spomenuti fragmenti su sami, konjugirani ili izmiješani.
7. Fragmenti seralizina za uporabu prema zahtjevu 5 ili 6, sami ili u kombinaciji, naznačeni time, da su dio spomenutog sastava kao molekularni agregati, sami, u kombinaciji između njih ili u kombinaciji s ostalim molekulama proteina ili ugljikohidrata.
8. Dijagnostički postupak in vitro za patološka stanja, naznačen time, da se odnosi na prekomjernu ekspresiju receptora faktora rasta i upalne bolesti, te obuhvaća uporabu fragmenata seralizina prema zahtjevima od 5 do 7, samih ili u kombinaciji.
9. Postupak skrininga za patološka stanja, naznačen time, da se odnosi na prekomjernu ekspresiju receptora faktora rasta i upalne bolesti, te obuhvaća uporabu fragmenata seralizina prema jednom od zahtjeva 5 do 7, samih ili u kombinaciji.
10. Sastav za uporabu prema bilo kojem od zahtjeva 1 do 4, naznačen time, da nadalje sadrži jedan ili nekoliko prodigiozina, pri čemu spomenuti prodigiozini pojačavaju protutumorsku aktivnost spomenutog sastava.
11. Sastav za uporabu prema bilo kojem od zahtjeva 1 do 4 i 10, naznačen time, da je za uporabu u liječenju patoloških stanja povezanih s angiogenezom, proliferativnim stanicama i imunološkim sustavom.
12. Sastav za uporabu prema bilo kojem od zahtjeva 1 do 4 i 10, naznačen time, da je za uporabu u liječenju patoloških stanja koja se mogu liječiti induciranjem antiproliferativnih, apoptotičnih, antiangiogenskih, imunomodulacijskih faktora ili regulacijskih faktora diferencijacije.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20040147A CU23475A1 (es) | 2004-07-08 | 2004-07-08 | Composición farmacéutica conteniendo fragmentos polipeptídicos de serralisinas |
| PCT/CU2005/000003 WO2006005268A2 (es) | 2004-07-08 | 2005-07-05 | Composición farmacéutica conteniendo fragmentos polipéptidicos de serralisinas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120682T1 true HRP20120682T1 (hr) | 2012-09-30 |
Family
ID=40259088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120682TT HRP20120682T1 (hr) | 2004-07-08 | 2012-08-27 | Protutumorski farmaceutski sastav koji sadr“i polipeptidne fragmente od seralizina |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8076297B2 (hr) |
| EP (1) | EP1787653B1 (hr) |
| JP (1) | JP4914350B2 (hr) |
| KR (1) | KR101365056B1 (hr) |
| AR (1) | AR050255A1 (hr) |
| AU (1) | AU2005262159B2 (hr) |
| BR (1) | BRPI0513136A (hr) |
| CA (1) | CA2572984C (hr) |
| CU (1) | CU23475A1 (hr) |
| CY (1) | CY1114201T1 (hr) |
| DK (1) | DK1787653T3 (hr) |
| ES (1) | ES2389126T3 (hr) |
| HR (1) | HRP20120682T1 (hr) |
| MX (1) | MX2007000339A (hr) |
| MY (1) | MY150858A (hr) |
| PL (1) | PL1787653T3 (hr) |
| PT (1) | PT1787653E (hr) |
| RS (1) | RS52448B (hr) |
| RU (1) | RU2396274C2 (hr) |
| SI (1) | SI1787653T1 (hr) |
| WO (1) | WO2006005268A2 (hr) |
| ZA (1) | ZA200700178B (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006056575A1 (en) * | 2004-11-23 | 2006-06-01 | Zymogenetics, Inc. | Purification of recombinant human factor xiii |
| EP2147327B1 (en) | 2007-05-04 | 2018-06-20 | Koninklijke Philips N.V. | Combination of mr and pet with correction for radiation absorption by an mr coil |
| CU23950B1 (es) | 2011-03-21 | 2013-10-29 | Ct De Ingeniería Genética Y Biotecnología | Péptidos cíclicos con actividad antineoplásica y antiangiogénica |
| TWI746449B (zh) * | 2015-07-20 | 2021-11-21 | 美商Ａｉ治療公司 | 使用阿吡莫德治療癌症之方法 |
| CN109295041A (zh) * | 2018-10-10 | 2019-02-01 | 宁波希诺亚海洋生物科技有限公司 | 具有舍雷肽酶活性的多肽及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58134991A (ja) * | 1981-12-28 | 1983-08-11 | Takeda Chem Ind Ltd | セラチオペプチタ−ゼの安定化法 |
| JP2611206B2 (ja) * | 1985-11-15 | 1997-05-21 | 武田薬品工業株式会社 | 遺伝子およびその利用方法 |
| KR100252197B1 (ko) * | 1997-09-20 | 2000-04-15 | 박호군 | 세라시아 마르세센스 균주의 배양액으로 부터 분리한 면역억제제용 프로디지오신 |
| US20040185566A1 (en) * | 2003-03-19 | 2004-09-23 | Peter Salamone | Polypeptides toxic to nematodes and methods of use |
-
2004
- 2004-07-08 CU CU20040147A patent/CU23475A1/es unknown
-
2005
- 2005-07-05 RU RU2007104776/13A patent/RU2396274C2/ru not_active IP Right Cessation
- 2005-07-05 ES ES05762122T patent/ES2389126T3/es active Active
- 2005-07-05 BR BRPI0513136-7A patent/BRPI0513136A/pt not_active Application Discontinuation
- 2005-07-05 DK DK05762122.9T patent/DK1787653T3/da active
- 2005-07-05 US US11/631,880 patent/US8076297B2/en not_active Expired - Fee Related
- 2005-07-05 PL PL05762122T patent/PL1787653T3/pl unknown
- 2005-07-05 SI SI200531578T patent/SI1787653T1/sl unknown
- 2005-07-05 RS RS20120391A patent/RS52448B/en unknown
- 2005-07-05 EP EP05762122A patent/EP1787653B1/en active Active
- 2005-07-05 WO PCT/CU2005/000003 patent/WO2006005268A2/es active Search and Examination
- 2005-07-05 JP JP2007519599A patent/JP4914350B2/ja not_active Expired - Fee Related
- 2005-07-05 KR KR1020077002589A patent/KR101365056B1/ko active IP Right Grant
- 2005-07-05 MX MX2007000339A patent/MX2007000339A/es active IP Right Grant
- 2005-07-05 AU AU2005262159A patent/AU2005262159B2/en not_active Ceased
- 2005-07-05 PT PT05762122T patent/PT1787653E/pt unknown
- 2005-07-05 CA CA2572984A patent/CA2572984C/en not_active Expired - Fee Related
- 2005-07-07 MY MYPI20053102 patent/MY150858A/en unknown
- 2005-07-08 AR ARP050102834A patent/AR050255A1/es active IP Right Grant
-
2007
- 2007-01-05 ZA ZA200700178A patent/ZA200700178B/xx unknown
-
2012
- 2012-08-27 HR HRP20120682TT patent/HRP20120682T1/hr unknown
- 2012-09-05 CY CY20121100800T patent/CY1114201T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2572984C (en) | 2014-12-09 |
| PT1787653E (pt) | 2012-09-06 |
| DK1787653T3 (da) | 2012-09-17 |
| SI1787653T1 (sl) | 2012-10-30 |
| EP1787653B1 (en) | 2012-06-06 |
| RS52448B (en) | 2013-02-28 |
| EP1787653A2 (en) | 2007-05-23 |
| US20110218138A1 (en) | 2011-09-08 |
| AR050255A1 (es) | 2006-10-11 |
| WO2006005268A2 (es) | 2006-01-19 |
| KR20070042542A (ko) | 2007-04-23 |
| CU23475A1 (es) | 2009-12-17 |
| MX2007000339A (es) | 2007-03-12 |
| US8076297B2 (en) | 2011-12-13 |
| RU2007104776A (ru) | 2008-08-20 |
| JP4914350B2 (ja) | 2012-04-11 |
| ZA200700178B (en) | 2008-06-25 |
| MY150858A (en) | 2014-03-14 |
| JP2008505129A (ja) | 2008-02-21 |
| KR101365056B1 (ko) | 2014-02-21 |
| PL1787653T3 (pl) | 2012-11-30 |
| BRPI0513136A (pt) | 2008-04-29 |
| ES2389126T3 (es) | 2012-10-23 |
| RU2396274C2 (ru) | 2010-08-10 |
| AU2005262159B2 (en) | 2011-08-18 |
| AU2005262159A1 (en) | 2006-01-19 |
| WO2006005268A3 (es) | 2006-03-09 |
| CY1114201T1 (el) | 2016-08-31 |
| CA2572984A1 (en) | 2006-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Passalacqua et al. | Stimulated astrocytes release high-mobility group 1 protein, an inducer of LAN-5 neuroblastoma cell differentiation | |
| HRP20120682T1 (hr) | Protutumorski farmaceutski sastav koji sadr“i polipeptidne fragmente od seralizina | |
| Li et al. | Bioactive silicate materials stimulate angiogenesis in fibroblast and endothelial cell co-culture system through paracrine effect | |
| Ferrara et al. | Bovine brain astrocytes express basic fibroblast growth factor, a neurotropic and angiogenic mitogen | |
| Olins et al. | The LINC-less granulocyte nucleus | |
| Hosseini et al. | Contribution of osteocalcin-mimetic peptide enhances osteogenic activity and extracellular matrix mineralization of human osteoblast-like cells | |
| Nakaji-Hirabayashi et al. | Hyaluronic acid hydrogel loaded with genetically-engineered brain-derived neurotrophic factor as a neural cell carrier | |
| Masuda-Murakami et al. | Effects of mineral trioxide aggregate on the differentiation of rat dental pulp cells | |
| BRPI0612273B8 (pt) | anticorpo de ligação a il-1 beta ou fragmento de ligação a il-1 beta do mesmo, ácido nucleico, vetor, e, composição | |
| ATE511857T1 (de) | Anti-april monoklonaler antikörper und deren verwendung zur behandlung von immunerkrankungen oder krebs | |
| JP2009524425A (ja) | 脂肪由来幹細胞を利用した成長因子の大量生産方法 | |
| Souza et al. | Regeneration of skin tissue promoted by mesenchymal stem cells seeded in nanostructured membrane | |
| Adamsky et al. | Glial tumor cell adhesion is mediated by binding of the FNIII domain of receptor protein tyrosine phosphatase β (RPTPβ) to tenascin C | |
| US20100112031A1 (en) | Compositions And Methods For Regulating Extracellular Matrix Production In Adipose Derived Cells | |
| EP3587440B1 (en) | Human pd-l1 high-protein-affinity peptide and use thereof | |
| You et al. | The effects of cerium valence states at cerium oxide coatings on the responses of bone mesenchymal stem cells and macrophages | |
| SK7012003A3 (en) | Fibroblast growth factors | |
| Li et al. | Tenascin C affects mineralization of SaOS2 osteoblast-like cells through matrix vesicles | |
| Wang et al. | Osteogenic differentiation of amniotic epithelial cells: synergism of pulsed electromagnetic field and biochemical stimuli | |
| KR20140030396A (ko) | 엘라스틴 유사 단백질 및 그 제조방법, 이를 이용한 신경세포의 분화방법 | |
| Mehta et al. | Amelioration of collagen antibody induced arthritis in mice by an antibody directed against the fibronectin type III repeats of tenascin-C: Targeting fibronectin type III repeats of tenascin-C in rheumatoid arthritis | |
| Nakaji-Hirabayashi et al. | Surface-anchoring of spontaneously dimerized epidermal growth factor for highly selective expansion of neural stem cells | |
| Gray et al. | Measurement of antibodies to collagen II by inhibition of collagen fibril formation in vitro | |
| Huang et al. | Neuron localization and neuroblastoma cell expression of brain-derived growth factor | |
| CN112679615B (zh) | 一种融合蛋白 |